Pair Name	Tanshinone IIA, Anti-mouse PD-1
Partner Name	Tanshinone IIA
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Immunomodulatory
Gene Regulation	Down-regulation	Expression	ADGRL4	hsa64123
	Up-regulation	Expression	CLDN5	hsa7122
	Down-regulation	Expression	JAK1	hsa3716
	Down-regulation	Expression	JAK2	hsa3717
	Up-regulation	Expression	OCLN	hsa100506658
	Up-regulation	Expression	TJP1	hsa7082
In Vitro Model	Jurkat	Childhood T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0065
	bEnd.3	Healthy	Mus musculus (Mouse)	CVCL_0170
	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
	CTLL-2	Healthy	Mus musculus (Mouse)	CVCL_0227
Result	This study reveals a new mechanism between TSA and ELTD1 for vascular normalization, suggesting that therapeutic or pharmacological intervention with ELTD1 may enhance the efficacy of PD-1 inhibitors in HCC.

Pair Name	Shikonin, Anti-mouse PD-1
Partner Name	Shikonin
Disease Info	[ICD-11: 2B91]	Colorectal cancer		Investigative
Gene Regulation	Down-regulation	Expression	CALR	hsa811
	Down-regulation	Expression	HMGB1	hsa3146
	Up-regulation	Expression	HSPA4	hsa3308
In Vitro Model	CT26	Mouse colon adenocarcinoma	Mus musculus (Mouse)	CVCL_7254
In Vivo Model	6×10⁵ CT26 cells were subcutaneously inoculated into BALB/c mice in the right inguinal region.
Result	Our study elucidated the potential role of 'Shikonin-PKM2-ROS-Hsp70' axis in the promotion of efficacy of PD-1 blockade in CRC treatments, providing a potential strategy and targets for improving the efficacy of PD-1 blockade in colorectal cancer.

Pair Name	Ginseng polysaccharides, Anti-mouse PD-1
Partner Name	Ginseng polysaccharides
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Immunomodulatory
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	NCI-H460	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0459
	NCI-H1299	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0060
In Vivo Model	Approximately 5×10⁵ Lewis lung cancer (LLC) cells and 5×104 B16-F10 cells were subcutaneously inoculated into the right flanks of mice.
Result	These results demonstrate that GPs combined with αPD-1 mAb may be a new strategy to sensitise non-small cell lung cancer patients to anti-PD-1 immunotherapy. The gut microbiota can be used as a novel biomarker to predict the response to anti-PD-1 immunotherapy.